Business Context and Reporting Period
This Form 8-K, filed on July 28, 2014, by Crane Co. (not Crane NXT, Co.), reports the results of operations for the quarter ended June 30, 2014. The filing primarily details significant updates regarding the Company's asbestos liability, including claim activity, litigation status, and financial estimates.
Key Financial Metrics: Asbestos Liability
The filing provides detailed financial data specific to asbestos-related costs and liabilities, rather than general operating revenue or profit metrics.
- Total Asbestos Liability: $659 million as of June 30, 2014 (down from $894 million recorded as of December 31, 2011).
- Current Portion of Liability: $88 million (estimated costs to be paid within the next 12 months).
- Insurance Receivable Asset: $162 million as of June 30, 2014 (estimated probable reimbursements).
- Cumulative Resolved Claims: Approximately 103,000 claims resolved through June 30, 2014, with total settlement costs of approximately $415 million.
- Average Settlement Cost: Approximately $4,000 per resolved claim cumulatively.
Asbestos Costs Incurred and Paid (Six Months Ended June 30, 2014)
| Item (in millions) | 2014 | 2013 |
|---|---|---|
| Total Costs Incurred (Settlement + Defense) | $45.0 | $43.1 |
| Pre-tax Cash Payments (Net of Insurance) | $30.8 | $28.9 |
| Settlement/Indemnity Costs Incurred | $15.2 | $14.3 |
| Defense Costs Incurred | $29.7 | $28.9 |
Material Changes and Litigation Updates
Claim Activity: As of June 30, 2014, there were 49,770 pending asbestos claims. This represents a decrease from 50,899 at the start of the quarter, driven by 1,540 dismissals and 251 settlements, offset by 662 new claims.
Significant Verdicts and Appeals:
- Ronald Dummitt (NY): A $4.9 million judgment was affirmed by the appellate court on July 3, 2014. The Company plans to appeal to the New York Court of Appeals.
- William Paulus (CA): The Company paid $0.9 million in June 2014 after exhausting all appeals on a judgment affirmed in February 2014.
- James Nelson (PA): A $4.0 million joint verdict was vacated by the Pennsylvania Superior Court in September 2013. An en banc reargument is scheduled for the third quarter of 2014.
- Recent Verdicts (June 2014): Juries entered $15 million and $10 million verdicts in the Ivan Sweberg and Selwyn Hackshaw claims (NY). The Company is filing post-trial motions and plans to appeal.
- Other Pending Appeals: Significant appeals remain pending in the Gerald Suttner (NY), James Hellam (CA), Thomas Amato/Frank Vinciguerra (PA), Ivo Peraica (NY), Lee Holdsworth (NY), Lloyd Garvin (SC), and Richard DeLisle (FL) matters.
Outlook, Risks, and Management Commentary
Liability Estimate Stability: Management determined that no change to the asbestos liability estimate was warranted for the period ended June 30, 2014. The estimate covers claims filed or projected through 2021. The Company does not believe costs beyond 2021 can be reasonably estimated.
Key Risk Factors:
- Uncertainty: The ultimate exposure is subject to significant uncertainties regarding the number of future claims, settlement costs, and defense costs.
- Interdependency: No single factor predominates in the liability estimate; factors such as new mesothelioma claims, average settlement costs, dismissal rates, and defense costs are interdependent.
- Insurance Recovery: The Company estimates a 25% reimbursement rate from insurers. This rate has not changed since December 2011, though actual reimbursements vary.
- Legislative and Judicial Trends: Changes in state legislation, judicial orders, or federal legislation could materially alter the liability estimate.
General Financials: The filing text does not provide specific values for general revenue, net income, operating margins, or total debt. These figures are referenced as being contained in the attached press release (Exhibit 99.1) and financial data supplement (Exhibit 99.2), which are not included in the source text.
Investor Verification Checklist
- Verify the specific revenue and earnings figures for the quarter ended June 30, 2014, in the attached Exhibit 99.1 (Press Release) and Exhibit 99.2 (Financial Supplement).
- Monitor the outcome of the en banc reargument in the James Nelson case (PA) scheduled for Q3 2014.
- Track the status of the Company's appeal to the New York Court of Appeals in the Ronald Dummitt case.
- Review the Company's quarterly updates on the 25% insurance recovery rate and the financial viability of its excess insurers.
- Assess the impact of the recent $25 million in combined verdicts (Sweberg and Hackshaw) on future cash flow projections, noting these are not yet accrued.